Goshe, Brett M.
Rasmussen, Autumn W.
Wagner, Lynne I.
Sicks, JoRean D.
Gareen, Ilana F.
Carlos, Ruth C.
Herman, Benjamin A.
Walter, Angela Wangari
Regan, Susan
Levy, Douglas E.
Mahon, Irene
Muzikansky, Alona
Neil, Jordan M.
Lui, Michelle
Dilip, Deepika
Malloy, Laura
Gonzalez, Irina
Finkelstein-Fox, Lucy
McCann, Caitlin
Perez, Elissa
Ostroff, Jamie S.
Park, Elyse R.
Funding for this research was provided by:
National Cancer Institute (R01CA214427)
Article History
Received: 17 May 2022
Accepted: 13 June 2022
First Online: 15 July 2022
Declarations
:
: The Centralized Institutional Review Board (CIRB) of the National Cancer Institute (NCI) approved the study protocol, ECOG-ACRIN-EAQ171CD. Additional human subjects’ approvals were obtained by Massachusetts General Brigham (MGB), Memorial Sloan Kettering Cancer Center (MSKCC), and Brown University review boards.The trial is monitored by the EA Data Safety and Monitoring Committee (DSMC). Eligible patients and site staff both provide written informed consent before participating in the study. This study follows current FDA, NCI, state, federal and institutional regulations concerning informed consent.
: Not applicable.
: RC: Salary support from JACR as editor-in-chief, Travel reimbursement from ARBIR, ARRS, RSNA. JO: reports receiving royalties from UpToDate. EPa: UpToDate chapter editor. BG, AR, LW, JS, IG, BH, AWW, SR, DL, IM, AM, JN, ML, DD, LM, IG, LFF, CM, EPe declare that they have no competing interests.